In brief
- Texas has launched phase 1 clinical trials for ibogaine, funded by the $50 million approved under state law SB 2308, with additional budget allocations added this week to cover trial costs.
- The program is led by UTHealth Houston alongside the University of Texas Medical Branch in Galveston, heading the IMPACT consortium, which brings together a dozen Texas universities and hospitals.
- The state decided to act as the trial sponsor after failing to find any pharmaceutical company willing to develop ibogaine for FDA approval.
The most unusual regulatory experiment in American psychedelic medicine is now underway. Texas, a state not typically known for its psychonautic enthusiasm, has begun phase 1 clinical trials of ibogaine—the alkaloid from the Tabernanthe iboga root—to treat opioid addiction, PTSD, and the sequelae of traumatic brain injury. There is no pharmaceutical company behind it: the state itself is the sponsor.
A state turned trial sponsor
Senate Bill 2308, passed in 2025, allocated $50 million in public funds to guide ibogaine through the FDA regulatory process. As reported by The Texas Tribune, the initiative was born with the expectation that a private company would co-finance the development, but none stepped forward. The compound has been in the public domain for decades and carries known cardiac risks that require close monitoring—a combination that is unattractive for private investment. Faced with this void, Lieutenant Governor Dan Patrick and the state House opted for Texas to assume the role of sponsor, an unprecedented move at this scale in the United States.
The IMPACT consortium
The contract was awarded to UTHealth Houston, in collaboration with the University of Texas Medical Branch (UTMB) in Galveston, leading an alliance dubbed IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma). The consortium includes, among others, Texas Tech, the University of Texas at Austin, San Antonio, Tyler, and the Rio Grande Valley, Texas A&M, Baylor College of Medicine, and the JPS Health Network in Dallas. According to the July 20 Psychedelics Today policy briefing, the first phase 1 trials have already launched, and the state has also approved supplemental budget reimbursements for trial costs, a sign that the program is moving forward with sustained political backing.
Why it matters
Ibogaine is experiencing a unique moment in the United States. As we reported a few days ago, the White House has ordered the coordination of six federal agencies to accelerate its clinical research. The Texas move adds a missing piece: public funding where private capital does not reach. Nevertheless, it is wise to maintain the caution we always advocate: ibogaine is not a benign substance—its effects on heart rhythm have caused deaths outside of clinical settings—and precisely for that reason, the framework of a trial with continuous cardiac monitoring is the appropriate place to answer whether its promising observational data in addiction holds up in a controlled trial. More context in our Iboga and Ibogaine Guide.
Sources
- Texas to conduct its own ibogaine clinical trials. The Texas Tribune, March 31, 2026.
- Psychedelic Policy Briefing: Week of July 20th, 2026. Psychedelics Today, July 20, 2026.
- Texas will launch its own clinical trials into ibogaine psychedelic. Texas Standard.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
